CA2501298A1 - Method of modifying the release profile of sustained release compositions - Google Patents

Method of modifying the release profile of sustained release compositions Download PDF

Info

Publication number
CA2501298A1
CA2501298A1 CA002501298A CA2501298A CA2501298A1 CA 2501298 A1 CA2501298 A1 CA 2501298A1 CA 002501298 A CA002501298 A CA 002501298A CA 2501298 A CA2501298 A CA 2501298A CA 2501298 A1 CA2501298 A1 CA 2501298A1
Authority
CA
Canada
Prior art keywords
microparticles
triamcinolone
sustained release
epo
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002501298A
Other languages
English (en)
French (fr)
Inventor
James R. Dasch
M. Gary I. Riley
Paul A. Burke
Susan A. Steitz-Abadi
Stephen E. Zale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2501298A1 publication Critical patent/CA2501298A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002501298A 2002-10-17 2003-10-08 Method of modifying the release profile of sustained release compositions Abandoned CA2501298A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41943002P 2002-10-17 2002-10-17
US60/419,430 2002-10-17
PCT/US2003/032017 WO2004034975A2 (en) 2002-10-17 2003-10-08 Sustained release profile modification

Publications (1)

Publication Number Publication Date
CA2501298A1 true CA2501298A1 (en) 2004-04-29

Family

ID=32108081

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002501298A Abandoned CA2501298A1 (en) 2002-10-17 2003-10-08 Method of modifying the release profile of sustained release compositions

Country Status (6)

Country Link
US (2) US20040121009A1 (https=)
EP (1) EP1567127A4 (https=)
JP (1) JP2006505562A (https=)
AU (1) AU2003284028B2 (https=)
CA (1) CA2501298A1 (https=)
WO (1) WO2004034975A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
SI2409707T1 (sl) * 2004-04-15 2015-07-31 Alkermes Pharma Ireland Limited Naprava s podaljšanim sproščanjem na osnovi polimerov
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2736184T3 (es) 2005-08-19 2019-12-26 Amylin Pharmaceuticals Llc Exendina para el tratamiento de la diabetes y la reducción del peso corporal
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
GR1005808B (el) * 2006-11-27 2008-02-06 Bionature E.A. Limited Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων
AU2008231093A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
EP2303313B1 (en) 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendins to lower cholestrol and triglycerides
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2014027253A1 (en) * 2012-08-14 2014-02-20 Wockhardt Limited Pharmaceutical microparticulate compositions of polypeptides
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DK0659073T3 (da) * 1992-09-10 2002-03-11 Childrens Medical Center Bionedbrydelige polymermatrixer med vedvarerende afgivelse af lokalanæstetika
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU677115B2 (en) * 1994-12-19 1997-04-10 University Of Miami Biodegradable injectable drug delivery polymer
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
GB9513118D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
WO1997044016A1 (en) * 1996-05-23 1997-11-27 Samyang Corporation Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US6203813B1 (en) * 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6248345B1 (en) * 1997-07-02 2001-06-19 Euro-Celtique, S.A. Prolonged anesthesia in joints and body spaces
AU752225B2 (en) * 1998-07-17 2002-09-12 Pacira Pharmaceuticals, Inc. Biodegradable compositions for the controlled release of encapsulated substances
PT1242121E (pt) * 1999-12-16 2005-05-31 Lilly Co Eli Composicoes polipeptidicas com estabilidade melhorada
JP2003533468A (ja) * 2000-02-28 2003-11-11 ゲル−デル テクノロジーズ，インコーポレイティド タンパク質マトリクス物質、製造並びにその製造及び使用
JP4733277B2 (ja) * 2001-02-08 2011-07-27 大洋薬品工業株式会社 徐放型マイクロカプセルの製造法
AU2003282955A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides

Also Published As

Publication number Publication date
WO2004034975A2 (en) 2004-04-29
US20040121009A1 (en) 2004-06-24
AU2003284028A1 (en) 2004-05-04
AU2003284028B2 (en) 2007-05-10
US20080057131A1 (en) 2008-03-06
EP1567127A2 (en) 2005-08-31
WO2004034975A3 (en) 2005-06-02
JP2006505562A (ja) 2006-02-16
EP1567127A4 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
US20080057131A1 (en) Method of modifying the release profile of sustained release compositions
US7164005B2 (en) Microencapsulation and sustained release of biologically active polypeptides
US20200390891A1 (en) Polymer-based sustained release device
AU2004319756B2 (en) Polymer-based sustained release device
AU2003217367B2 (en) Polymer-based compositions for sustained release
US7282216B2 (en) Biocompatible polymer blends and uses thereof
US20150224176A1 (en) Pharmaceutical microparticulate compositions of polypeptides
US20150258198A1 (en) Pharmaceutical microparticulate compositions of polypeptides
WO2001058428A1 (en) Method of preparing a sustained release composition

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued